Venlafaxine Induces Psychiatric Disorders Due to Upregulation of Cerebral Catechol-O-methyltransferase Via the PI3K/AKT/mTOR Pathway
Li Liu,Liqiang Qian,Hanyu Yang,Q Ye,Zijun Xu,Yanlin Liu,Zehua Wang,Wei Wu,Xiaodong Liu
DOI: https://doi.org/10.21203/rs.3.rs-3206277/v1
2023-01-01
Abstract:Clinical use of venlafaxine often leads to several central nervous system adverse events, but its mechanisms are still unclear. We observed obvious impairments in locomotor and exploration activities during open-field and tail-suspension tests in venlafaxine-treated rats and mice, which indicated that venlafaxine could induce the anxiety-like behavior with co-morbid depressive-like behavior in experimental animals. Different from the accepted opinion that altered dopamine (DA) or 5-hydroxytryptamine (5-HT) levels could induce psychiatric disorders, venlafaxine treatment did not affect the levels of DA and 5-HT, but significantly decreased levels of 3,4-Dihydroxyphenylacetic acid (DOPAC) and increased levels of homovanillic acid (HVA). Catechol-O-methyltransferase (COMT) mediates the formation of HVA from DOPAC. Further investigation found that venlafaxine significantly upregulated the expression and activity of COMT, whilst decreasing levels of S-adenosylmethionine (SAM, a methyl-donor), histone H3 lysine 4 trimethylation (H3K4me3), and histone H3 lysine 27 trimethylation (H3K27me3) in the cortexes of rats and mice. Treatment of COMT inhibitor tolcapone or SAM attenuated venlafaxine-induced psychiatric disorders and decreases in cerebral SAM, H3K4me3, and H3K27me3 levels. In vitro , venlafaxine and mTOR activator MHY1485 also led to upregulations in COMT expression and decreases in levels of SAM, H3K4me3, and H3K27me3, whilst tolcapone and SAM attenuated these changes. Phosphatidylinositol 3-kinase (PI3K) inhibitor LY294002, mammalian target of rapamycin (mTOR) inhibitor rapamycin, and silencing ribosomal protein 70 S6 kinase ( P70S6K ) or eIF4E-binding protein 1 ( 4EBP1 ) remarkably attenuated the induction of COMT by venlafaxine. Significantly increased phosphorylation levels of AKT, P70S6K, and 4EBP1 were also detected in the cortexes of venlafaxine-treated rats and mice. These results indicate that venlafaxine induces COMT expression via activating the PI3K/AKT/mTOR pathway, leading to decreases in levels of SAM, H3K4me3, and H3K27me3, which ultimately results in the occurrence of several psychiatric symptoms.